ZIM Labs is a pioneer in developing Oral Thin Films (“OTF”) an innovative and novel drug delivery dosage form. The above product is developed using patented Thinoral technology, which yields instantly wettable, rapidly dissolving, and stable orally dissolving films.
The conventional dosage form such as tablet and capsule are difficult to administer, may poses choking hazards and unfriendly to patient convenience. Against the odds of drug intake, oral thin film dissolves instantly after placing on the tongue and results in faster action. Unique features of OTFs and it’s flexibility offers unparalleled convenience in drug handling and administration.
According to various global research institutions, the market of sildenafil is expected to gain healthy growth in the forecast period of 2021 to 2028.Rising adoption of sedentary lifestyle and increasing incidence of lifestyle diseases are further anticipated to fuel the growth.
Dr. Anwar Daud, Chairman & Managing Director of ZIM Laboratories, gladly commented on the authorization, “The marketing approval for Sildenafil Oral Thin Films can be viewed as a further assurance that ZIM laboratories with it’s R&D capabilities and high quality manufacturing standards can become a promising partner for the overseas clients who look for the cost effective innovative drug delivery solutions to meet global market challenges and cater the needs of patients and medical professionals”.
At around 11:29 AM, ZIM Laboratories was trading flat at Rs190 per piece on the BSE.
#ZIM #Laboratories #announces #grant #marketing #authorization #Sildenafil #Spain #Europe
( With inputs from indiainfoline)